Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy

New England Journal of Medicine

Volumn 359, Issue 3, 2008, Pages 320-321

  Lees, Charles W ^a   Ironside, Janet ^a   Wallace, William A H ^b   Satsangi, Jack ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

AGED; CASE REPORT; CLUBBING FINGERS; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REMISSION; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; LUNG TUMOR; RADIOGRAPHY; SMOKING;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CROHN DISEASE; FEMALE; HUMANS; LUNG NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47549113100     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0800250     Document Type: Letter

References (5)

1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. [Erratum, JAMA 2006;295:2482.]
2. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
3. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
4. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-34.
5. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7.